Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | COMT | P21964 | 1/20 | 0.44 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | RAD52 | P43351 | 1/20 | 0.41 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18713208 | 0.84 | MC4R (0.55) | KMT2AALDH1A1CHRNA7KDM4ETDP1 | |
| SCHEMBL10211060 | 0.83 | CFB (0.50) | KMT2AALDH1A1MEN1KDM4ETDP1 | |
| SCHEMBL10702627 | 0.82 | COMT (0.47) | KMT2AALDH1A1KDM4ECOMTTP53 | |
| SCHEMBL16340100 | 0.82 | KMT2A (0.50) | KMT2AALDH1A1MEN1KDM4EERAP1 | |
| SCHEMBL806920 | 0.82 | CFB (0.53) | KMT2AALDH1A1MEN1CHRNA7KDM4E | |
| SCHEMBL18704987 | 0.79 | KDM4E (0.48) | KMT2AALDH1A1MEN1KDM4ETDP1 | |
| SCHEMBL918507 | 0.78 | KMT2A (0.41) | KMT2AALDH1A1MEN1KDM4ECOMT | |
| SCHEMBL20965553 | 0.78 | ALDH1A1 (0.62) | KMT2AALDH1A1MEN1CHRNA7KDM4E | |
| SCHEMBL917995 | 0.78 | LMNA (0.64) | KMT2AMEN1TDP1 | |
| SCHEMBL24403536 | 0.78 | KMT2A (1.00) | KMT2AALDH1A1MEN1KDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119103-B2 | Bifunctional resorcinol, thioresorcinol, and dithioresorcinol derivative metal chelating conjugates | MALLINCKRODT LLC (US) | 2012-02-21 | — | — | US | disclosed |
| US-20090082324-A1 | Bifunctional Resorcinol, Thioresorcinol, and Dithioresorcinol Derivative Metal Chelating Conjugates | INFACARE PHARMACEUTICAL CORPORATION | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082324-A1 | Bifunctional Resorcinol, Thioresorcinol, and Dithioresorcinol Derivative Metal Chelating Conjugates | SPR, QDPR, SLC40A1 | KMT2A 1441/4885ALDH1A1 716/4885MEN1 1017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.